CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：New insights into CAR T cell-mediated killing of tumor cells.
New insights into CAR T cell-mediated killing of tumor cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
表达嵌合抗原受体（CAR）的T细胞过继转移在治疗多种血液系统恶性肿瘤方面显示出显著疗效，包括B细胞淋巴瘤、白血病和多发性骨髓瘤。然而，CAR-T 细胞在大多数实体瘤中的疗效非常有限。在此背景下，理解决定CAR-T 细胞成功与失败的决定因素至关重要。为了控制肿瘤生长，CAR-T 细胞需要通过组装免疫突触与其靶标形成结合体。在此，我们综述了近期进展，这些进展表明实体瘤中CAR-T 细胞与癌细胞之间的黏附随时间以IFN和ICAM-1依赖的方式增强，从而导致CAR-T 细胞介导的杀伤。我们讨论了如何利用这些发现来提高CAR-T 细胞策略对抗实体瘤的疗效。
Adoptive transfer of T cells genetically engineered to express chimeric antigen receptors (CAR) has demonstrated striking efficacy for the treatment of several hematological malignancies, including B-cell lymphoma, leukemia, and multiple myeloma.
However, CAR T-cell efficacy has been very limited in most solid tumors. In this context, it is of paramount importance to understand the determinants that condition CAR T-cell success versus failure. To control tumor growth, CAR T cells need to form conjugates with their targets via the assembly of an immunological synapse.
Here, we review recent advances showing that the adhesion between CAR T cells and cancer cells from solid tumors strengthens over time in an IFN - and ICAM-1-dependent manner, resulting in CAR T cell-mediated killing.
We discuss how these findings can be exploited to increase the efficacy of the CAR T-cell strategy against solid tumors.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
